Independent prognostic variables in acute myeloid leukaemia.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Blood reviews

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.blre.2010.10.002PMID 21078537
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Retinoic Acid: Result of the Randomized MRC Trial All-Trans Predict Prognosis in Acute Promyelocytic Leukemia Treated With Presenting White Blood Cell Count and Kinetics of Molecular Remission

  2013cited by this paper
• Cytogenetics of Acute Leukemia

  2013cited by this paper
• Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?

  2011cited by this paper
• Therapy-related acute promyelocytic leukemia

  2011cited by this paper
• Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.

  2010cited by this paper
• The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

  2010cited by this paper
• Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

  2010cited by this paper
• IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.

  2010cited by this paper
• Quantitative DNA methylation predicts survival in adult acute myeloid leukemia.

  2010cited by this paper
• Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

  2010cited by this paper
• Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.

  2010cited by this paper
• Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.

  2010cited by this paper
• High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.

  2010cited by this paper
• Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.

  2010cited by this paper
• IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

  2010cited by this paper
• Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

  2010cited by this paper
• The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.

  2010cited by this paper
• Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

  2010cited by this paper
• Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study

  2010cited by this paper
• OGG1 is a novel prognostic indicator in acute myeloid leukaemia

  2010cited by this paper
• The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA

  2010cited by this paper
• BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

  2010cited by this paper
• DNMT3A mutations in acute myeloid leukemia.

  2010cited by this paper
• Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.

  2010cited by this paper
• DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

  2010cited by this paper
• Prognostic Importance of MN 1 Transcript Levels , and Biologic Insights From MN 1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia : A Cancer and Leukemia Group B Study

  2009cited by this paper
• Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis

  2009cited by this paper
• Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

  2009cited by this paper
• A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects.

  2009cited by this paper
• IDH 1 and IDH 2 Mutations in Gliomas

  2009cited by this paper
• Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

  2009cited by this paper
• Mutation in TET2 in myeloid cancers.

  2009cited by this paper
• AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.

  2009cited by this paper
• Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

  2009cited by this paper
• Mutation in TET2 in myeloid cancers.

  2009cited by this paper
• Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.

  2009cited by this paper
• Autonomous growth potential of leukemia blast cells is associated with poor prognosis in human acute leukemias

  2009cited by this paper
• TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis

  2009cited by this paper
• CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome Subtypes

  2009cited by this paper
• Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives

  2009cited by this paper
• Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

  2009cited by this paper
• CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

  2009cited by this paper
• Independent prognostic factors for AML outcome.

  2009cited by this paper
• New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia.

  2009cited by this paper
• Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.

  2009cited by this paper
• Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.

  2009cited by this paper
• Recurring mutations found by sequencing an acute myeloid leukemia genome.

  2009cited by this paper
• microRNAs in acute myeloid leukemia: Expression patterns, correlations with genetic and clinical parameters, and prognostic significance

  2009cited by this paper
• Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.

  2009cited by this paper
• Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity

  2009cited by this paper
• The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

  2009cited by this paper
• New insights to the MLL recombinome of acute leukemias

  2009cited by this paper
• The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia

  2009cited by this paper
• Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• TET2 mutations in myelodysplasia and myeloid malignancies

  2009cited by this paper
• Survival is poorer in patients with secondary core‐binding factor acute myelogenous leukemia compared with de novo core‐binding factor leukemia

  2009cited by this paper
• Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

  2009cited by this paper
• Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.

  2009cited by this paper
• Acute myelogenous leukemia.

  2009cited by this paper
• The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication.

  2009cited by this paper
• Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

  2009cited by this paper
• Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.

  2008cited by this paper
• Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.

  2008cited by this paper
• Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.

  2008cited by this paper
• Genetics of therapy-related myelodysplasia and acute myeloid leukemia

  2008cited by this paper
• MicroRNA expression in cytogenetically normal acute myeloid leukemia.

  2008cited by this paper
• MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients.

  2008cited by this paper
• High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.

  2008cited by this paper
• FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.

  2008cited by this paper
• Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

  2008cited by this paper
• An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.

  2008cited by this paper
• Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

  2008cited by this paper
• Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease.

  2008cited by this paper
• Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.

  2008cited by this paper
• Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.

  2008cited by this paper
• MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.

  2008cited by this paper
• The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

  2008cited by this paper
• Development of minimal residual disease-directed therapy in acute myeloid leukemia.

  2008cited by this paper
• Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia

  2008cited by this paper
• Response: Still a need for more robust evidence that FLT3/ITD status should influence the decision to proceed to transplantation in AML patients

  2007cited by this paper
• Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis.

  2007cited by this paper
• Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

  2007cited by this paper
• Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?

  2007cited by this paper
• Impact of Cytogenetics on Clinical Outcome in AML

  2007cited by this paper
• High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.

  2007cited by this paper
• Survival Is Poorer in Patients with Secondary Core Binding Factor Acute Myelogenous Leukemia Compared with De Novo Core Binding Factor Leukemia.

  2007cited by this paper
• The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.

  2007cited by this paper
• Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

  2007cited by this paper
• Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.

  2007cited by this paper
• Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

  2007cited by this paper
• Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.

  2007cited by this paper
• Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention

  2007cited by this paper
• FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.

  2007cited by this paper
• Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations

  2007cited by this paper
• Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

  2006cited by this paper
• A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies

  2006cited by this paper
• Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML.

  2006cited by this paper
• Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.

  2006cited by this paper
• Age and acute myeloid leukemia.

  2006cited by this paper

• Case Report: Late Hypersensitivity Reaction to Hydroxyurea in a Patient With Myeloproliferative Disorder

  2025cites this paper
• Emerging roles for the RXFP1 in myeloid series leukemia

  2024influential citation
• Association of CYP1A1*2C Variant (Ile464Val Polymorphism) and Some Hematological Parameters with Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML) in Erbil-Iraq.

  2023cites this paper
• Quantitative tumor burden imaging parameters of the spleen at MRI for predicting treatment response in patients with acute leukemia

  2023cites this paper
• BSG (CD147) Serum Level and Genetic Variants Are Associated with Overall Survival in Acute Myeloid Leukaemia

  2022cites this paper
• Survival of Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: An Experience in Developing Country

  2022cites this paper
• Significance of CD200 expression in patients with acute myeloid leukemia and its correlation with other prognostic markers

  2022cites this paper
• Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia

  2021cites this paper
• Ultimate Precision: Targeting Cancer But Not Normal Self-Replication

  2021cites this paper
• Mayo Clinic experience with 1123 adults with acute myeloid leukemia

  2021cites this paper
• Discovery of A Myeloid Sarcoma in A Hemodialysis Patient: Don’t Miss the Prior Hematological History!

  2020cites this paper
• Effect and safety of gemtuzumab ozogamicin for the treatment of patients with acute myeloid leukaemia: a systematic review protocol

  2020cites this paper
• Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.

  2020cites this paper
• Cytogenetic Pattern in Adult Patients with de novo Acute Myeloid Leukaemia: A Single Centre Study in Bangladesh

  2020cites this paper
• Cytogenetic and molecular genetic methods for chromosomal translocations detection with reference to the KMT2A/MLL gene

  2020cites this paper
• Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications

  2020cites this paper
• Cell‐based and antibody‐mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues

  2020cites this paper
• Role of Endoglin Expression in Acute Myeloblastic Leukemia

  2019cites this paper
• Chapter 2 Genetic Mechanisms and Molecular Markers of Neoplastic Transformation in Acute Myeloid Leukemia

  2019influential citation
• Hibridación in situ fluorescente (FISH) en el Instituto Nacional de Cancerología (INC) de Colombia. Experiencia de 5 años

  2019influential citation
• Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML

  2019cites this paper
• 14 Prognosis and Survival in Acute Myelogenous Leukemia

  2018cites this paper
• Investigation of cell cycle status in patients with acute myeloid leukaemia

  2018cites this paper
• From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia

  2018cites this paper
• Leukemogenic nucleophosmin mutation disrupts the transcription factor hub regulating granulo-monocytic fates

  2018cites this paper
• Acute Myeloid Leukemia with Complex Hyperdiploid Karyotype: A Case Report

  2018cites this paper
• Precision Molecular Pathology of Myeloid Neoplasms

  2018cites this paper
• A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia

  2018cites this paper
• Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates

  2018cites this paper
• Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells

  2018cites this paper
• Ultimate Precision: Targeting Cancer but Not Normal Self-replication.

  2018cites this paper
• CD30 Expression vs. Serum Soluble CD30 (sCD30) Level: Role in Prognosis and Treatment of Acute Myeloid Leukaemia

  2017cites this paper
• ABCB1 genetic variants in leukemias: current insights into treatment outcomes

  2017cites this paper
• Characteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia.

  2017cites this paper
• Acute Leukemia Characteristics are Different Around the World: the Mexican Perspective

  2017cites this paper
• Cytogenetic and Molecular Genetic Prognostic Factors of Acute Myeloid Leukemia

  2017cites this paper
• Monosomal karyotype in myeloid neoplasias: a literature review

  2017cites this paper
• CD30 EXPRESSION VERSUS SERUM S MARKERS IN *Dalia

  2017influential citation
• 高三尖杉酯碱、阿糖胞苷、柔红霉素或去甲氧柔红霉素(HAD/HAI)诱导治疗初治急性髓系白血病的长期疗效分析

  2016cites this paper
• 60 mg·m−2·d−1柔红霉素联合标准剂量阿糖胞苷诱导治疗≤65岁初治急性髓系白血病患者的疗效和安全性分析

  2016cites this paper
• The Genetic Basis of Haematological Cancers: Tosi/The Genetic Basis of Haematological Cancers

  2016cites this paper
• Critical Updates to the Leukemia Stem Cell Model

  2016cites this paper
• [Analysis of the safety and efficacy of 60 mg·m-2·d-1daunorubicin combined with standard dose of cytarabine as induction therapy in acute myeloid leukemia patients under 65 years old].

  2016cites this paper
• Acute myeloid leukemia—Major progress over four decades and glimpses into the future

  2016cites this paper
• Hispidulin induces mitochondrial apoptosis in acute myeloid leukemia cells by targeting extracellular matrix metalloproteinase inducer.

  2016cites this paper
• Examination of the FLT3 and NPM1 mutational status in patients with acute myeloid leukemia from southeastern Poland

  2016cites this paper
• Impact pronostique de la maladie résiduelle par quantification des mutations d'IDH1/2 par PCR digitale dans les leucémies aiguës myéloïdes incluses dans les protocoles alfa-0701 et 0702

  2016cites this paper
• Prognostic Value of BAALC Expression in Pediatric Acute Myeloid Leukemia: A Systematic Review

  2016cites this paper
• Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance.

  2016cites this paper
• Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long‐term outcome

  2015cites this paper
• Clinical usefulness of fluorescence in situ hybridization for detection of MLL rearrangements in acute myeloid leukemia

  2015cites this paper
• Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors

  2015cites this paper
• New Heterogeneity of the Leukemic Stem Cells

  2015cites this paper
• ADVANCES IN ACUTE MYELOID LEUKEMIA Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance Cytogenetic analyses of large cohorts of AML patients

  2015cites this paper
• Characterisation and Clinical Significance of FLT3-ITD and non-ITD in Acute Myeloid Leukaemia Patients in Kelantan, Northeast Peninsular Malaysia.

  2015cites this paper
• shRNA-Mediated EMMPRIN Silencing Inhibits Human Leukemic Monocyte Lymphoma U937 Cell Proliferation and Increases Chemosensitivity to Adriamycin

  2015cites this paper
• Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis.

  2014cites this paper
• Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine

  2014cites this paper
• The pterocarpanquinone LQB-118 induces apoptosis in acute myeloid leukemia cells of distinct molecular subtypes and targets FoxO3a and FoxM1 transcription factors

  2014cites this paper
• To establish the role of mutations in c-KIT tyrosine kinase in the pathogenesis and therapy of core-binding factor-related acute myeloid leukaemia (AML)

  2014influential citation
• Markers for Diagnosis, Prognosis, and Therapy of Acute Myeloid Leukemia

  2014influential citation
• RETRACTED ARTICLE: shRNA-Mediated EMMPRIN Silencing Inhibits Human Leukemic Monocyte Lymphoma U937 Cell Proliferation and Increases Chemosensitivity to Adriamycin

  2014cites this paper
• Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial

  2014influential citation
• smpx-deficient zebrafish embryos: a tool for studying ciliopathies and deafness

  2014cites this paper
• Granulocytic Sarcoma (Chloroma) Presenting as Multiple Sites in Oral Cavity: Report of a Case

  2014cites this paper
• Impact des comorbidités sur le pronostic des patients âgés de plus de 75 ans traités par azacitidine pour myélodysplasie de haut risque ou leucémie aiguë myéloblastique

  2014cites this paper
• Acute myeloid leukaemia

  2014cites this paper
• Oncogenic fusion proteins expressed in immature hematopoietic cells fail to recapitulate the transcriptional changes observed in human AML

  2014cites this paper
• adolescents: recommendations from an international expert panel Diagnosis and management of acute myeloid leukemia in children and

  2013cites this paper
• Old and new prognostic factors in acute myeloid leukemia with deranged core‐binding factor beta

  2013cites this paper
• Identification of Circulating MicroRNAs as Potential Biomarkers for Detecting Acute Myeloid Leukemia

  2013cites this paper
• The therapeutical potential of a novel pterocarpanquinone LQB-118 to target inhibitor of apoptosis proteins in acute myeloid leukemia cells.

  2013cites this paper
• The FLT3 Tyrosine Kinase in Leukemia : Deciphering the Downstream Signaling Events and Drug-Escape Mechanisms

  2013cites this paper
• CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes.

  2013cites this paper
• The Development and Validation of a Decision-Analytic Model Representing the Full Disease Course of Acute Myeloid Leukemia

  2013cites this paper
• Chapter 9 Role of Cytogenetic Analysis in the Diagnosis and Classification of Hematopoietic Neoplasms

  2013cites this paper
• Immunotherapeutic strategies for relapse control in acute myeloid leukemia.

  2013cites this paper
• Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.

  2013cites this paper
• A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse

  2013cites this paper
• Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: a multicenter retrospective study.

  2013cites this paper
• A novel t(4;16)(q25;q23.1) associated with EGF and ELOVL6 deregulation in acute myeloid leukemia.

  2013cites this paper
• 뀀Ƞ THE FLT3 TYROSINE KINASE IN LEUKEMIA

  2013cites this paper
• Investigating the mechanism underlying modulation of ATRA response by the transcription factor EVI1

  2013cites this paper
• Small-molecule inhibition of BRD 4 as a new potent approach to eliminate leukemic stem-and progenitor cells in acute myeloid leukemia ( AML )

  2013cites this paper
• L’intégration du séquençage de nouvelle génération dans le diagnostic médical : application aux leucémies aiguës myéloïdes et syndromes myélodysplasiques

  2013cites this paper
• Regeneration-associated WNT signaling is activated in long-term reconstituting AC133bright acute myeloid leukemia cells.

  2012cites this paper
• Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia

  2012cites this paper
• Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)

  2012cites this paper
• 189 – The Acute Leukemias

  2012cites this paper
• Studies on CEBPA mutations in acute myeloid leukaemia

  2012cites this paper
• Genetic Mechanisms and Molecular Markers of Neoplastic Transformation in Acute Myeloid Leukemia

  2012influential citation
• Acute myeloid leukemia with adverse cytogenetic risk.

  2012cites this paper
• Prognostic markers in AML: focus on CBFL.

  2012cites this paper
• Prognosis and Survival in Acute Myelogenous Leukemia

  2012influential citation
• Minimal Residual Disease as a Predictive Factor for Relapse after Allogeneic Hematopoietic Stem Cell Transplant in Adult Patients with Acute Myeloid Leukemia in First and Second Complete Remission

  2012cites this paper
• Studies of New Signal Transduction Modulators in Acute Myeloid Leukemia

  2012cites this paper
• FLT 3 internal tandem duplication and JAK 2 V 617 F mutations in de novo acute myelogenous leukemia : relation with induction chemotherapy and overall survival

  2012cites this paper
• The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

  2012cites this paper
• Combined effects of FLT3 and NF‐κB selective inhibitors on acute myeloid leukemia in vivo

  2012cites this paper
• Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns

  2012cites this paper